{"id":"NCT04674358","sponsor":"Aldeyra Therapeutics, Inc.","briefTitle":"The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease","officialTitle":"The TRANQUILITY Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-11-21","primaryCompletion":"2021-09-12","completion":"2021-09-12","firstPosted":"2020-12-19","resultsPosted":"2025-03-19","lastUpdate":"2025-03-19"},"enrollment":329,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye","Dry Eye Syndromes"],"interventions":[{"type":"DRUG","name":"Reproxalap Ophthalmic Solution (0.25%)","otherNames":[]},{"type":"DRUG","name":"Vehicle Opthalmic Solution","otherNames":[]}],"arms":[{"label":"Reproxalap Ophthalmic Solution (0.25%) administered QID over two consecutive days.","type":"EXPERIMENTAL"},{"label":"Vehicle Ophthalmic Solution administered over two consecutive days.","type":"PLACEBO_COMPARATOR"}],"summary":"The TRANQUILITY Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease.","primaryOutcome":{"measure":"Conjunctival Redness Assessed Over 90 Minutes in the Dry Eye Chamber","timeFrame":"The efficacy assessment period was assessed during the 90-minute dry eye chamber at Day 2; baseline was Pre-Dose #1 at Day 1.","effectByArm":[{"arm":"Reproxalap Ophthalmic Solution (0.25%)","deltaMin":0.185,"sd":0.0233},{"arm":"Vehicle","deltaMin":0.156,"sd":0.0229}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":164},"commonTop":["General disorders and administration site conditions"]}}